The Effect of Chitosan as Internal or External Coating on the 5-ASA Release from Calcium Alginate Microparticles

The effect of chitosan as internal or external coating on the mesalamine (5-ASA) release from calcium alginate microparticles (CaAl) was studied, and a delayed release of 5-ASA system intended for colonic drug delivery was developed. The external chitosan coating was developed by immersion of wetted CaAl in chitosan solution and the internal coating by mixing 5-ASA with chitosan solution and drying before the preparation of CaAl. Both systems were coated with Acryl-EZE^® using combined fluid bed coating and immersion procedure. The results showed that in phosphate medium (pH 7.5), chitosan as 5-ASA coating promotes a quick erosion process accelerating drug release, but chitosan as external coating (CaAlCS) does not increase the T ₅₀ value compared with the microparticles without chitosan (CaAl). Chitosan as internal or external coating was not effective to avoid the quick 5-ASA release in acidic medium (pH 1.2). The presence of β-glucosidase enzymes increases significantly the 5-ASA release for CaAl, while no effect was observed with chitosan as internal or external coating. Fourier transform infrared spectroscopy, thermogravimetric analysis, and X-ray data revealed that 5-ASA did not form a solid solution but was dispersed in the microparticles. The Acryl-EZE^® coating of microparticles was effective because all the formulations showed a low release, less than 15%, of 5-ASA in acid medium at pH 1.2. Significant differences in the percentage of 5-ASA released between formulations were observed in phosphate buffer at pH 6.0. In phosphate buffer at pH 7.2, all the formulations released 100% of 5-ASA.     

胰岛素强化治疗对胃癌围手术期营养代谢的影响：随机对照研究

目的:探讨胃癌围手术期能量及营养物质的代谢特点,研究强化胰岛素治疗对围手术营养代谢的影响.方法:选取胃中、下部癌病理诊断明确并且外科病房ICU住院时间不少于24h的患者64例,取得知情同意后随机分到强化胰岛素治疗(IIT)血糖控制在4.4～6.1 mmol/L.和传统治疗(CIT)组血糖控制在10mmol/L以下;应用CCM营养代谢监测系统测定围手术期静息能量消耗(REE),呼吸商(RQ),每公斤体重静息能量消耗(REE/kg)和脂肪氧化比率,应用多频人体生物电阻抗分析仪测定围手术期人体组分的变化及应用稳态模式评估法计算胰岛素抵抗指数(HOMA-IR).结果:64例病人入选,每组32例,手术创伤引起术后第1、3天REE水平增加约22%和12%,呼吸商降低至0.759和0.791,REE/kg增加28 kcal/kg和26 kcal/kg,脂肪氧化比率增加至78%和65%,Ln-HOMA-IR明显增加(P<0.05);IIT治疗能降低术后第1、3天Ln-HOMA-IR和REE/kg水平;术后人体指标如细胞内液、脂肪组织、蛋白组织、肌肉组织、瘦体组织和体质量较术前水平明显降低(P<0.05);IIT能明显减少脂肪组织、蛋白组织和细胞内液的消耗量(P=0.009,t=0.026).结论:IIT能够有效降低胃癌围手术期胰岛素抵抗程度、降低静息能量消耗的水平和减少脂肪及蛋白质的消耗.     

Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis

Optimizing the metabolism of the myocardium is a new strategy for patients with ischemic heart disease. Many studies have reported beneficial effects of trimetazidine (TMZ) on the clinical prognosis of patients with ischemic heart disease, but whether these beneficial effects are extended to patients undergoing percutaneous coronary intervention (PCI) remains uncertain. A meta-analysis was performed to evaluate the effect of TMZ on patients undergoing PCI. We conducted an electronic search of PubMed, Cochrane databases, the China National Knowledge Infrastructure, and Chinese Biological Medicine Database to identify randomized controlled trials. Methodological quality was assessed according to the Jadad scale score, and the meta-analysis was performed using Cochrane Collaboration RevMan 5.2 and Comprehensive Meta-Analysis. Dichotomous data were analyzed using relative risk (RR) or odds ratio (OR) with effect size indicated by the 95% confidence interval (CI), and continuous variables were analyzed using weighted mean differences (WMD) with effect size indicated by the 95% CI. Sensitivity analysis was performed by changing the statistical methods and effect model. Nine studies involving a total of 778 patients were included in this meta-analysis. Additional use of TMZ significantly improved the left ventricular ejection fraction (WMD: 3.11, 95% CI: [2.26, 3.96]) and reduced elevated cardiac troponin Ic level (RR: 0.69, 95% CI: [0.48, 0.99]), angina attacks during PCI (OR: 0.16, 95% CI: [0.07, 0.38]), and ischemic ST-T changes on the echocardiogram during PCI (RR: 0.76, 95% CI: [0.59, 0.98]). However, no significant difference was observed in serum BNP level 30 days after PCI between the experimental and control group. Additional use of TMZ for patients undergoing PCI may reduce myocardial injury during the procedure and improve cardiac function.     

Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Background and Purpose

Selecting an ideal antithrombotic therapy for elderly patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) can be challenging since they have a higher thromboembolic and bleeding risk than younger patients. The current study aimed to assess the efficacy and safety of triple therapy (TT: oral anticoagulation plus dual antiplatelet therapy: aspirin plus clopidogrel) in patients ≥75 years of age with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI).

Methods

A prospective multicenter study was conducted from 2003 to 2012 at 6 Spanish teaching hospitals. A cohort study of consecutive patients with AF undergoing PCI and treated with TT or dual antiplatelet therapy (DAPT) was analyzed. All outcomes were evaluated at 1-year of follow-up.

Results

Five hundred and eighty-five patients, 289 (49%) of whom were ≥75 years of age (79.6±3.4 years; 33% women) were identified. TT was prescribed in 55.9% of patients at discharge who had a higher thromboembolic risk (CHA₂DS₂VASc score: 4.23±1.51 vs 3.76±1.40, p = 0.007 and a higher bleeding risk (HAS-BLED ≥3: 88.6% vs 79.2%, p = 0.02) than those on DAPT. Therefore, patients on TT had a lower rate of thromboembolism than those on DAPT (0.6% vs 6.9%, p = 0.004; HR 0.08, 95% CI: 0.01–0.70, p = 0.004). Major bleeding events occurred more frequently in patients on TT than in those on DAPT (11.7% vs 2.4%, p = 0.002; HR 5.2, 95% CI: 1.53–17.57, p = 0.008). The overall mortality rate was similar in both treatment groups (11.9% vs 13.9%, p = 0.38); however, after adjustment for confounding variables, TT was associated with a reduced mortality rate (HR 0.33, 95% CI: 0.12–0.86, p = 0.02).

Conclusions

In elderly patients with AF undergoing PCI, the use of TT compared to DAPT was associated with reduced thromboembolism and mortality rates, although a higher rate of major bleeding.     

Health-Related Quality of Life in Patients with Nonfunctioning Pituitary Adenomas Undergoing Postoperative Radiation Therapy: A Case-Control Study

Objective: Nonfunctioning pituitary adenomas (NFPAs) can be associated with significant morbidity including a compromised quality of life (QoL). Radiotherapy (RT) is listed as one of the contributing factors to QoL impairment in these patients, however the evidence supporting this association is scarce and conflicting. Here we evaluate health-related QoL (HRQoL) impairment in patients with NFPA and to what extent this is due to RT.Methods: HRQoL was evaluated with the short form-36 questionnaire (SF-36), which explores 8 domains pertaining physical, emotional, and mental well being. We assessed 50 patients with NFPA subjected to RT after pituitary surgery, and their results were compared to those from 127 subjects who had undergone surgery but not RT. Both groups were matched for age, sex, and metabolic and cardiovascular comorbidities. The SF-36 was applied a median of 72 months after RT in the group of cases and 78 months after the last surgical procedure in the control group.Results: Both groups scored equally low in the 8 areas explored by the survey. In a multiple linear regression model, age was significantly associated with worse physical health scores, whereas female sex was associated with worse general health perception and lower emotional role and physical role scores. The presence of a visual field defect was significantly associated with a worse social role functioning score.Conclusion: QoL in patients with NFPAs is significantly compromised in most scales evaluated by the SF-36 survey. However, RT itself does not affect QoL.Abbreviations:CI = confidence intervalGH = growth hormoneHRQoL = health-related quality of lifeIQR = interquartile rangeNFPA = nonfunctioning pituitary adenomaQoL = quality of lifeRT = radiotherapySF-36 = short form 36-item health surveyTSS = transsphenoidal surgeryXRT = external beam radiotherapy     

Evaluation of ADA Gene Expression and Transduction Efficiency in ADA/SCID Patients Undergoing Gene Therapy

A capillary electrophoresis (CE) method was developed for ADA/SCID diagnosis and monitoring of enzyme replacement therapy, as well as for exploring the transfection efficiency for different retroviral vectors in gene therapy.     

术前参观对冠状动脉介入治疗患者焦虑的影响

目的:探讨术前参观对择期进行心脏介入术患者心理焦虑的影响。方法:将400例择期行心脏介入手术的患者分为参观组和对照组,对照组术前采用常规护理干预,参观组患者在此基础上进行术前参观,熟悉环境,了解手术过程。调查比较两组患者术前2日及术前1小时的焦虑值。结果:参观组与对照组术前2日焦虑值无明显差异,术前1小时参观组焦虑值明显低于对照组,差异具有统计学意义(P0.05)。结论:通过术前参观能够减轻患者的焦虑程度。     

Hepatic Enzyme Alterations in HIV Patients on Antiretroviral Therapy: A Case-Control Study in a Hospital Setting in Ghana

Background

Diagnosing hepatic injury in HIV infection can be a herculean task for clinicians as several factors may be involved. In this study, we sought to determine the effects of antiretroviral therapy (ART) and disease progression on hepatic enzymes in HIV patients.

Methods

A case-control study conducted from January to May 2014 at the Akwatia Government Hospital, Eastern region, Ghana, The study included 209 HIV patients on ART (designated HIV-ART) and 132 ART-naive HIV patients (designated HIV-Controls). Data gathered included demography, clinical history and results of blood tests for hepatic enzymes. We employed the Fisher’s, Chi-square, unpaired t-test and Pearson’s correlation in analysis, using GraphPad Prism and SPSS. A P value < 0.05 was considered significant.

Results

Median CD4 lymphocyte count of HIV-ART participants (604.00 cells/mm³) was higher than that of HIV-Controls (491.50 cells/mm3; P = 0.0005). Mean values of ALP, ALT, AST and GGT did not differ between the two groups compared (P > 0.05). There was a significant positive correlation between hepatic enzymes (ALP, ALT, AST and GGT) for both groups (p < 0.01 each). Duration of ART correlated positively with ALT (p < 0.05). The effect size of disease progression on hepatic enzymes for both groups was small.

Conclusion

Antiretroviral therapy amongst this population has minimal effects on hepatic enzymes and does not suggest modifications in therapy. Hepatic injury may occur in HIV, even in the absence of ART and other traditional factors. Monitoring of hepatic enzymes is still important in HIV patients.     

Regulatory Phenotype,PD-1 and TLR3 Expression in T Cells and Monocytes from HCV Patients Undergoing Antiviral Therapy: A Randomized Clinical Trial

Background & Aims

The cellular immunity has a profound impact on the status of hepatitis C virus (HCV) infection. However, the response of cellular immunity on the virological response in patients with antiviral treatment remains largely unclear. We aimed to clarify the response of peripheral T cells and monocytes in chronic hepatitis C patients with antiviral treatment.

Methods

Patients with chronic hepatitis C were treated either with interferon alpha-2b plus ribavirin (n = 37) or with pegylated interferon alpha-2a plus ribavirin (n = 33) for up to 24 weeks. Frequencies of peripheral regulatory T-cells (Tregs), programmed death-1 (PD-1) expressing CD4⁺ T-cells or CD8⁺ T-cells and toll-like receptor (TLR) 3 expressing CD14⁺ monocytes were evaluated by flow cytometry in patients at baseline, 12 and 24 weeks following treatment and in 20 healthy controls.

Results

Frequencies of Tregs, PD-1 and TLR3 expressing cells were higher in patients than those in control subjects (P<0.05). Patients with complete early virological response (cEVR) showed lower Tregs, PD-1 expressing CD4⁺ or CD8⁺ T-cells than those without cEVR at 12 weeks (P<0.05). Patients with low TLR3 expressing CD14⁺ monocytes at baseline had a high rate of cEVR (P<0.05).

Conclusions

Low peripheral TLR3 expressing CD14⁺ monocytes at baseline could serve as a predictor for cEVR of antiviral therapy in chronic HCV-infected patients. The cEVR rates were significantly increased in the patients with reduced circulating Tregs, PD-1 expressing CD4⁺ or CD8⁺ T-cells.

Trial Registration

Chinese Clinical Trial Registry ChiCTR10001090.     

Predictors of Outcome and Hemorrhage in Patients Undergoing Endovascular Therapy with Solitaire Stent for Acute Ischemic Stroke

Background

Endovascular mechanical thrombectomy is emerging as a promising therapeutic approach for acute ischemic stroke and show some advantages. However, the data of predicting clinical outcome after thrombectomy with Solitaire retriever were limited. We attempt to identify prognostic factors of clinical outcome in patients with acute ischemic stroke undergoing thrombectomy with Solitaire retriever.

Methods

We conducted a retrospective analysis of consecutive acute ischemic strokes cases treated between December 2010 and December2013 where the Solitaire stent retriever was used for acute ischemic stroke. We assessed the effect of selected demographic characteristics, clinical factors on poor outcome at 3 months (modified Rankin score 3–6), mortality at 3 months, and hemorrhage within 24 h (symptomatic and asymptomatic). Clinical, imaging and logistic variables were analyzed. A multivariate logistic regression analysis was used to identify variables influencing clinical outcome, based on discharge NIHSS score change and mRS at 3 months.

Results

Eighty nine consecutive patients with acute ischemic stroke underwent mechanical thrombectomy. Multivariate analysis revealed that admission NIHSS score, Serum glucose and endovascular procedure duration were independently associated with clinical outcome. Sex, NIHSS score at admission, diabetes and time of operation were associated with sICH in 1 day. NIHSS score ≥20 (OR 9.38; 95% CI 2.41–36.50), onset to reperfusion >5 hours (OR 5.23; 95% CI1.34,20.41) and symptomatic intracranial hemorrhage (OR 10.19; 95% CI1.80,57.83) were potential predictive factors of mortality at 3 months.

Conclusion

Multiple pre- and intra-procedural factors can be used to predict clinical outcome, symptomatic intracranial hemorrhage and mortality in acute ischemic stroke patients undergoing endovascular therapy. This knowledge is helpful for patients selection for endovascular mechanical thrombectomy.     

主动脉内球囊反搏术对行经皮冠状动脉介入术AMI合并CS患者的影响及术后院内死亡的危险因素分析

摘要 目的：分析主动脉内球囊反搏术（IABP）对行经皮冠状动脉介入术（PCI）急性心肌梗死（AMI）合并心源性休克（CS）患者的影响及术后院内死亡的危险因素。方法：选取2020年6月-2022年5月我院收治的105例AMI合并CS患者,将直接行PCI治疗患者设为对照组（n=59例）,行IABP辅助支持下PCI治疗患者设为研究组（n=46例）。比较两组术后心脏指标[左室射血分数（LVEF）、左室舒张末期内径（LVEDD）和左室收缩末期内径（LVESD）]、心肌酶谱指标[心肌肌钙蛋白T与肌钙蛋白I、肌酸激酶同工酶（CK-MB）]、术后主要心血管不良事件。根据患者出院时是否存活分为存活组（n=74）与死亡组（n=31）,比较两组临床资料,采用多因素Logistic回归模型分析患者院内死亡的危险因素。结果：术后两组LVEF较术前提高,LVEDD、LVESD降低,且研究组LVEF高于对照组,LVEDD、LVESD低于对照组（P＜0.05）。术后两组心肌酶谱指标较术前显著下降,且研究组肌钙蛋白I、肌钙蛋白T、CK-MB水平低于对照组（P＜0.05）。术后对照组发生5例再发心肌梗死、7例急性血栓形成,研究组分别为2例、3例（P＞0.05）;对照组死亡23例,研究组死亡8例,研究组死亡人数低于对照组（P＜0.05）。死亡组年龄、Killip分级≥Ⅲ级、高血脂、LVEF＜40%、TIMI血流分级≤Ⅱ级占比、白细胞计数、血肌酐水平高于存活组,收缩压、舒张压、血红蛋白、肌钙蛋白I、肌钙蛋白T、CK-MB、LVEF、IABP辅助低于存活组（P＜0.05）。多因素Logistic回归分析显示,年龄≥65岁、Killip分级≥Ⅲ级、LVEF＜40%、TIMI血流分级≤Ⅱ级为患者院内死亡的危险因素（P＜0.05）。结论：IABP辅助支持下的PCI能有效改善AMI合并CS患者心功能,年龄≥65岁、Killip分级≥Ⅲ级、LVEF＜40%、TIMI血流分级≤Ⅱ级为等为其院内死亡危险因素。     

右美托咪定对腰硬联合麻醉下手术病人镇静效果分析

目的:探究右美托咪定对腰硬联合麻醉下手术病人镇静效果.方法:选取我院于2008年9月-2011年4月收治的腰硬联合麻醉下手术患者160例,按照随机数字表平均分为观察组及对照组,各80例,分别在麻醉后注射右美托咪定及生理盐水,观察两组患者BIS、Ramsay、心率等镇静指标,并观测血流动力学变化,探讨右美托咪定的镇静效果及安全性.结果:观察组BIS术前与术中BIS指数分别为93.8±4.9及65.2±3.6,Ramsay评分分别为2.1±0.5及4.0± 0.8,心率分别为71.5±5.8及60.7± 4.2,上述三项指标术中与术前数据存在明显统计学差异,且与对照组同一时期对比存在统计学差异,血压指标两组组间及术前、术中对比均不存在统计学差异;观察组出现6例心动过缓,5例低血压,并发症发生率13.8％,对照组出现5例心动过缓,5例低血压,并发症发生率12.5％,两组患者并发症情况对比无明显统计学差异.结论:右美托嘧啶能够有效改善腰硬联合麻醉手术患者的BIS指标、Ramsay得分及心率情况,能够阻滞痛觉的传导、降低心率,从而起到镇静、止痛作用,且不会带来更多的麻醉应激反应,效果及安全性均有良好的保障,值得临床推广.     

优质护理在腹腔镜子宫肌瘤剔除术患者术后护理效果研究

为探讨优质护理在腹腔镜子宫肌瘤剔除术患者术后护理中的应用价值。本研究选取接受腹腔镜子宫肌瘤剔除术治疗的140例患者作为研究对象,采用随机数字表分为优质组(优质护理模式)、常规组(常规护理模式)各70例,比较两组患者干预前后的生存质量(GQOL-74评分)、简明心境状态测试(pOMS)量表评分的变化。结果显示,干预前,优质组和常规组患者的角色功能、躯体功能、心理功能、社会功能、GQOL-74量表总体评分差异无统计学意义(p>0.05);干预后,优质组患者的角色功能、躯体功能、心理功能、社会功能、GQOL-74量表总体评分均显著高于常规组(p<0.05);干预前,优质组和常规组患者的抑郁、疲劳、紧张、愤怒、慌乱、精力、与自我有关的情绪评分差异无统计学意义(p>0.05);干预后,优质组患者的精力、与自我有关的情绪评分均显著高于常规组(p<0.05),优质组患者的抑郁、疲劳、紧张、愤怒、慌乱评分均显著低于常规组(p<0.05)。本研究表明优质护理在腹腔镜子宫肌瘤剔除术患者术后护理中能有效改善患者的生存质量及不良心境情绪。     

封包联合窄波UVB治疗寻常型银屑病疗效观察及护理体会

目的:探讨封包联合窄波UVB治疗寻常型银屑病疗效及护理方法。方法:自2010年2月至2011年8月到我院治疗的142例寻常型银屑病患者分为两组,治疗组予封包联合窄波UVB治疗并配合精心护理,对照组仅予封包治疗,两组均在治疗6周后观察症状及体征的变化。患者治疗后随访半年。结果:治疗组较对照组第4周PASI评分(4.33±3.23 vs 6.24±3.35)和第6周PASI评分(2.32±2.02 vs 3.68±2.52)明显降低,有统计学差异(P<0.05)。治疗组与对照组有效率分别为85.89%和67.19%,差异有显著统计学意义(P<0.01)。随访半年结果治疗组复发率较对照组少(P<0.05)。结论:封包联合窄波UVB治疗寻常型银屑病并配合精心护理能够取得良好的临床治疗效果。     

Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy

Objective

Based on drug-drug interaction, dose reduction of rifabutin is recommended when co-administered with HIV protease inhibitors for human immunodeficiency virus (HIV)-associated mycobacterial infection. The aim of this study was to compare the pharmacokinetics of rifabutin administered at 300 mg/day alone to that at 150 mg every other day combined with lopinavir-ritonavir in Japanese patients with HIV/mycobacterium co-infection.

Methods

Plasma concentrations of rifabutin and its biologically active metabolite, 25-O-desacetyl rifabutin were measured in 16 cases with HIV-mycobacterial coinfection. Nine were treated with 300 mg/day rifabutin and 7 with 150 mg rifabutin every other day combined with lopinavir-ritonavir antiretroviral therapy (ART). Samples were collected at a median of 15 days (range, 5–63) of rifabutin use.

Results

The mean C_max and AUC_0–24 of rifabutin in patients on rifabutin 150 mg every other day were 36% and 26% lower than on 300 mg/day rifabutin, while the mean C_max and AUC_0–24 of 25–O-desacetyl rifabutin were 186% and 152% higher, respectively. The plasma concentrations of rifabutin plus its metabolite were similar between the groups within the first 24 hours, but it remained low during subsequent 24 to 48 hours under rifabutin 150 mg alternate day dosing.

Conclusion

Rifabutin dose of 150 mg every other day combined with lopinavir-ritonavir seems to be associated with lower exposure to rifabutin and its metabolite compared with rifabutin 300 mg/day alone in Japanese patients. Further studies are needed to establish the optimal rifabutin dose during ART. The results highlight the importance of monitoring rifabutin plasma concentration during ART.

Trial registration

UMIN-CTR (https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=search&action=input&language=E) UMIN000001102     

Role of Probiotics in Oral Health Maintenance Among Patients Undergoing Fixed Orthodontic Therapy: a Systematic Review of Randomized Controlled Clinical Trials

The aim was to assess the role of probiotics in oral health maintenance among patients undergoing fixed orthodontic therapy (OT). An unrestricted search of indexed databases was performed until April 2020 using the following Mesh-terms: (1) probiotic and (2) orthodontic. Randomized controlled clinical trials (RCTs) evaluating the influence of probiotic therapy (PT) towards oral health maintenance/improvement in patients undergoing fixed OT were included. Data screening, selection, and extraction were performed; and the risk of bias was assessed using the Cochrane Collaboration’s tool. All evaluations were performed by 2 independent researchers; and disagreements were resolved via discussion. Nine RCTs were included. Eight studies reported that PT improves oral health in patients undergoing fixed OT. Seven studies showed that PT reduces the counts of oral pathogenic bacteria in the oral biofilm and/or saliva. One study reported that PT reduces halitosis in patients undergoing fixed OT. One study found that PT reduces the scores of plaque index (PI) and gingival index (GI); and one study reported that PT has no significant influence on PI and GI in patients undergoing fixed OT. One study reported that PT does not prevent the formation of white spot lesions during fixed OT. Three and 6 studies had a moderate and low risk of bias, respectively. A power analysis was performed in 4 studies. In conclusion, probiotics exhibit antimicrobial activity against oral pathogenic bacteria; however, due to the limitations of the studies assessed, further well-designed RCTs are needed.

     

不同粘度对比剂对冠状动脉造影患者肾功能的影响

目的：对比剂肾病（CIN）是介入治疗中常见并发症之一。由于对比剂肾病发病机制复杂,其确切的机制尚不明确,有研究认为应用渗透压相似的对比剂,高粘度组对比剂引起CIN的几率明显高于低粘度组。本研究探讨接受不同粘度对比剂冠状动脉造影检查的患者术后引起肾功能损害的差异及其可能的机制。方法：80例接受冠状动脉造影检查的患者随机分为两组。分别为20℃碘海醇组、37℃碘海醇组,每组各40例。分别于冠脉造影前8h、冠脉造影后48h采集同一患者肘正中静脉血进行血清肌酐（Scr）、血清胱抑素C（CysC）检测,并对数据进行统计学分析。结果：两组患者组间比较基本资料无明显差异,两组患者术后Ser、CysC较术前均升高,差异均有统计学意义（P〈0．05）;20℃碘海醇组术后Scr较37℃碘海醇组升高不明显,差异无统计学意义（P〉0．05）;20℃碘海醇组术后CysC较37℃碘海醇组升高明显,差异有统计学意义（P〈0．05）。结论：冠脉造影检查时．对比剂对患者的肾功能有损害;选择低粘度对比剂可能减少其对冠状动脉造影患者的肾功能的不良影响;其作用机制可能与对比剂改变血液粘滞性,从而影响肾血流有关。     

帕瑞昔布联合曲马多用于腹腔镜胆囊切除术术后镇痛

目的:观察帕瑞昔布联合应用曲马多用于腹腔镜胆囊切镇痛的作用效果评价。方法:72例行腹腔镜胆囊切除术的患者,随机分成3组,每组24例。A组与B组术前15 min静注帕瑞昔布0.8mg/kg,C组手术结束前10 min静注帕瑞昔布0.8mg/kg;术毕A组静注生理盐水20 mL,B组与C组静注曲马多1 mg/kg。分别记录术毕给药后1、3、6、12、24 h的视觉模拟评分(VAS评分),不良反应及患者对镇痛治疗的总体满意度。结果:B组VAS评分在术后24h内各时间点均低于A组和C组(P<0.05);3组术后不良反应无显著差异(P>0.05);B组镇痛药物用量明显少于A、C组(P<0.05);患者对镇痛治疗总体满意度B组与A组、C组比较均有统计学意义(P<0105)。结论:帕瑞昔布术前应用具有超前镇痛作用,同时联合应用曲马多,可以提高镇痛质量,是腹腔镜胆囊切除术患者术后镇痛的良好选择。     

帕瑞昔布联合曲马多用于腹腔镜胆囊切除术术后镇痛

目的:观察帕瑞昔布联合应用曲马多用于腹腔镜胆囊切镇痛的作用效果评价.方法:72例行腹腔镜胆囊切除术的患者,随机分成3组,每组24例.A组与B组术前15 min静注帕瑞昔布0.8mg/kg,C组手术结束前10 min静注帕瑞昔布0.8mg/kg;术毕A组静注生理盐水20 mL,B组与C组静注曲马多1 mg/kg.分别记录术毕给药后1、3、6、12、24h的视觉模拟评分(VAS评分),不良反应及患者对镇痛治疗的总体满意度.结果:B组VAS评分在术后24h内各时间点均低于A组和C组(P＜0.05);3组术后不良反应无显著差异(P＞0.05);B组镇痛药物用量明显少于A、C组(P＜0.05);患者对镇痛治疗总体满意度B组与A组、C组比较均有统计学意义(P＜ 0105).结论:帕瑞昔布术前应用具有超前镇痛作用,同时联合应用曲马多,可以提高镇痛质量,是腹腔镜胆囊切除术患者术后镇痛的良好选择.